Biotech Values

[biotech_researcher]

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
Jan 18, 2022

PDF Version
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range

Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives

Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022

https://investors.impelnp.com/news-releases/news-release-details/impel-neuropharma-provides-updates-trudhesatm-launch-and-recent/

31 million migraine suffers in the US. Unique upper nasal delivery pod which targets blood vessel rich area. Achieves IV Efficacy for pain. Only 23 million shares in float. 80% owned by institutions.